[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Seoul National University Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":638},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,195,0,25,[9,45,73,95,116,144,168,186,204,233,263,291,311,336,360,387,416,438,460,480,517,539,560,597,619],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100569830","pacing-of-left-bundle-branch-area-and-atroventricular-node-ablation-in-patients-with-symptomatic-atrial-fibrillation-100569830",false,"NCT06699342","Pacing of Left Bundle Branch Area and Atroventricular Node ablatIon in Patients With Symptomatic Atrial Fibrillation","PALLIATE-AF","Inclusion:\n\nPatients who meet all of the following inclusion criteria 1)-6).\n\n1. Permanent atrial fibrillation\n2. Age ≥ 65 years\n3. Refractory or intolerant to antiarrhythmic drugs, rate control medications, or catheter ablation\n4. New York Heart Association (NYHA) functional class II- IV\n5. LVEF \\> 40% (within the past 3 months)\n6. Patients with at least one of the following:\n\n   1. HF hospitalization (defined as HF as the major reason for hospitalization or treatment for HF lasting ≥12 hours and including treatment with intravenous (IV) diuretics at a healthcare facility) within 12 months\n   2. Elevated NT-proBNP (\\>900 pg\u002Fml) in the 30 days prior to enrollment\n\nExclusion:\n\nPatients who meet at least one of the following exclusion criteria 1)-11).\n\n1. Asymptomatic atrial fibrillation\n2. Life expectancy to \\\u003C 12 months.\n3. Primary moderate to severe valvular disease (except for functional mitral valve regurgitation or tricuspid valve regurgitation)\n4. Mechanical tricuspid valve replacement\n5. Severe chronic kidney disease (estimated Glomerular Filtration Rate ≤ 15 ml\u002F1,73 m2 or receiving renal replacement treatment including hemodialysis or peritoneal dialysis)\n6. Obstructive hypertrophic cardiomyopathy\n7. Infiltrative cardiomyopathy (amyloidosis, sarcoidosis, Fabry disease, others)\n8. Acute coronary syndrome or coronary revascularization (CABG or PCI) \\\u003C3 months\n9. Severe primary pulmonary disease such as cor pulmonale, irreversible lung disease requiring inhalers, oxygen supplementation\n10. Pacemaker\u002FICD\u002FCRT treatment ongoing, or current pacemaker indication\n11. Simultaneous participation in a different randomized clinical trial","ALL","65 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aimed to compare the clinical outcomes of left bundle branch area pacing combined with atrioventricular node ablation and pharmacologic treatment optimized according to guidelines in patients with symptomatic atrial fibrillation refractory or intolerant to drug therapy or catheter ablation.",[27],"Atrial Fibrillation (AF)",[29,30,31],"atrial fibrillation","left bundle branch area pacing","Atrioventricular node ablation","RECRUITING","2026-08-19",{"date":35,"type":36},"2026-08-20","ACTUAL",{"date":38,"type":36},"2025-01-27",{"date":40,"type":21},"2027-12-31",{"name":42,"class":43},"Seoul National University Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100575558","phase-2-building-evidence-for-ablative-internal-radiation-therapy-in-localized-hcc-beyond-the-up-to-7-criteria-100575558","NCT06773845","Building Evidence for Ablative Internal Radiation Therapy in Localized HCC Beyond the Up-To-7 Criteria","Building Evidence for Ablative Internal Radiation Therapy Using Yttrium-90 Glass Microspheres in Localized Hepatocellular Carcinoma Beyond the Up-To-7 Criteria","BEAT-UT7","Inclusion criteria\n\n* Adult aged 19 and over\n* HCC diagnosed by histology or non-invasive criteria of the American Association for the Study of Liver Disease\n* Unresectable HCC beyond the UT7 criteria: the sum of the diameter of the largest tumor (cm) and the number of tumors \\> 7\n* Localized HCC: all tumors are in the one to five geographically adjacent Couinaud segments\n* No current or previous HCC in the untreated liver (i.e., future liver remnant \\[FLR\\])\n* FLR volume \\> 30% of total non-tumorous liver volume\n* Child-Pugh class A\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1\n* No major organ dysfunction according to blood test performed within two months of study enrollment:\n\n  * Leukocytes ≥ 2,000\u002FµL and ≤ 15,000\u002FµL\n  * Hemoglobin ≥ 8.0 g\u002FdL (transfusion allowed to meet this criterion)\n  * Total bilirubin ≤ 2.0 mg\u002FdL\n  * Platelet ≥ 40,000\u002FµL\n  * International normalized ratio (INR) ≤ 2.0 for patients not taking anticoagulants\n  * Aspartate transaminase (AST) ≤ 200 IU\u002FL (i.e., ≤ 5X upper normal limit)\n  * Alanine transaminase (ALT) ≤ 200 IU\u002FL (i.e., ≤ 5X upper normal limit)\n  * Creatinine ≤ 2.5 mg\u002FdL\n* Patients with a life expectancy of more than 3 months\n* For women of childbearing age, a negative serum pregnancy test\n* Patients who have adequately understood the clinical trial and consented in writing\n\nExclusion Criteria:\n\n* HCC with vascular invasion and\u002For bile duct invasion on dynamic computed tomography (CT) or magnetic resonance imaging (MRI)\n* HCC with extrahepatic spread on chest CT and abdominal CT or MRI\n* Multinodular disseminated HCC: largest tumor size \\\u003C 6 cm, or number of tumors \\> 10\n* Patients who are not suitable for ablative radioembolization as indicated by pre-treatment mapping with 99mTc-macroaggregated albumin (MAA):\n\n  * Cases where the estimated lung dose exceeds 30 Gy when 350 Gy of tumor absorbed dose is administered to the tumor based on the multicompartment Medical Internal Radiation Dose (MIRD) model\n  * Cases with severe hepatic artery-portal vein shunting that might lead to irradiation of the non-tumorous liver segments\n  * Cases where the operator determines that there is substantial adhesion with the surrounding organs such as the bowel, making ablative radioembolization infeasible\n* Cases where the operator judges that the occurrence of even mild radiation pneumonitis could be fatal, based on marked emphysema or interstitial lung disease findings on chest CT\n* Patients who have had active cancer within the last two years prior to the study enrollment\n* History of severe allergy of intolerance to contrast agents\n* Contraindication to angiography or selective visceral catheterization","19 Years",{"count":55,"type":21},100,[57],"PHASE2","At four major centers in Korea, patients with hepatocellular carcinoma (HCC) that exceed the up-to-7 criteria yet remain locally confined will undergo ablative radioembolization using Yttrium-90 glass microspheres, guided by a standardized dosimetry method. Their treatment response, survival outcomes, and adverse events will be monitored for two years following the procedure.",[60,61],"Hepatocellular Carcinoma (HCC)","Radioembolization",[63,61,64],"Hepatocellular carcinoma","SIRT","2026-08-18",{"date":35,"type":36},{"date":68,"type":36},"2025-03-11",{"date":70,"type":21},"2030-12-31",{"name":42,"class":43},8,{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":89,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":44},"100529778","phase-2-radiation-major-hepatectomy-to-selectively-treat-large-unifocal-hepatocellular-carcinoma-100529778","NCT06178198","Radiation Major Hepatectomy to Selectively Treat Large Unifocal Hepatocellular Carcinoma","An Open-label, Single-arm, Single-center Clinical Trial to Evaluate the Efficacy and Safety of Yttrium-90 Ablative Radioembolization (Radiation Major Hepatectomy) for Unifocal Large Hepatocellular Carcinoma","RESCUE","Inclusion Criteria:\n\n1. Adults aged 18 and over.\n2. Patients diagnosed with hepatocellular carcinoma histologically and\u002For radiologically (LI-RADS 4 or 5).\n3. Patients with no more than five lesions in dynamic contrast-enhanced CT or MRI, and the largest tumor diameter exceeding 8 cm.\n4. Patients without vascular invasion and bile duct invasion in dynamic contrast-enhanced CT or MRI.\n5. Patients with no extrahepatic metastasis in lung CT and contrast-enhanced abdominal CT or MRI.\n6. Patients with no prior treatment for liver cancer.\n7. Child-Pugh class A.\n8. ECOG performance status of 1 or less.\n9. Patients with no major organ dysfunction according to blood tests performed within one month of study enrollment.\n\n   1. Leukocytes ≥ 2,500\u002FµL and ≤ 12,000\u002FµL\n   2. Absolute neutrophil count ≥ 1,500 \u002Fmm\\^3\n   3. Hemoglobin ≥ 8.0 g\u002FdL (transfusion allowed to meet this criterion)\n   4. Total bilirubin ≤ 3.0 mg\u002FdL\n   5. Platelet ≥ 50,000\u002FµL\n   6. INR ≤ 2.0 for patients not taking anticoagulants\n   7. AST ≤ 200 IU\u002FL (i.e., ≤ 5X upper normal limit)\n   8. ALT ≤ 200 IU\u002FL (i.e., ≤ 5X upper normal limit)\n   9. ALP ≤ 575 IU\u002FL (i.e., ≤ 5X upper normal limit)\n   10. Creatinine ≤ 2.0 mg\u002FdL\n10. Patients with a life expectancy of more than 3 months.\n11. Patients who have adequately understood the clinical trial and consented in writing.\n12. Non-pregnant women of childbearing potential.\n\nExclusion Criteria:\n\n1. Patients who are not suitable for ablative radioembolization as indicated by pre-treatment testing with macro-aggregated albumin labeled with technetium-99 (99mTc-MAA) for radioembolization.\n\n   1. Cases where the estimated lung dose exceeds 15 Gy when 150 Gy of absorbed dose is administered to the tumor based on the partition method.\n   2. Cases with severe hepatic artery-portal vein shunting that might lead to irradiation of the non-tumorous liver segments.\n2. Patients whose volume of non-tumorous liver not included in the treatment area is less than 30% of the total non-tumorous liver volume.\n3. Patients scheduled to use immunotherapy irrespective of the response to radioembolization.\n4. Patients who have had active cancer within the last two years prior to the clinical trial participation.\n5. Patients who have undergone surgery or procedures related to the bile duct.\n6. Women who are pregnant or breastfeeding.","18 Years",{"count":83,"type":21},30,[57],"The RESCUE trial is a prospective, single-arm clinical study to evaluate the efficacy and safety of ablative radioembolization using Yttrium-90. This treatment is being investigated as a potential curative approach, as well as a bridging or downstaging strategy for surgery, in patients with large hepatocellular carcinoma (greater than 8 cm) who maintain good liver function.",[87],"Hepatocellular Carcinoma",[87,61],{"date":35,"type":36},{"date":91,"type":36},"2023-11-08",{"date":93,"type":21},"2026-11-30",{"name":42,"class":43},{"id":96,"slug":97,"hasResults":12,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":22,"phases":104,"briefSummary":105,"conditions":106,"keywords":107,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":109,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},"100528884","phase-2-radioembolization-as-a-spearhead-treatment-of-hepatocellular-carcinoma-with-localized-portal-vein-tumor-thrombosis-100528884","NCT06166576","Radioembolization as a Spearhead Treatment of Hepatocellular Carcinoma With Localized Portal Vein Tumor Thrombosis","An Open-label, Prospective, Multi-center Clinical Trial to Evaluate the Efficacy and Safety of Ablative Radioembolization Using Yttrium-90 Glass Microspheres in Patients With Locally-advanced Hepatocellular Carcinoma","RESOLVE","Inclusion Criteria:\n\n1. Adults aged 18 and over\n2. Patients diagnosed with unilobar hepatocellular carcinoma, either histologically and\u002For radiologically (LI-RADS 4 or 5)\n3. Patients with at least one measurable lesion greater than 10 mm on dynamic contrast-enhanced CT or MRI\n4. Patients with localized portal vein invasion limited in one lobe (Vp1-3) on dynamic contrast-enhanced CT or MRI\n5. Patients with no extrahepatic metastasis on lung CT and contrast-enhanced abdominal CT or MRI\n6. Patients with no prior treatment for liver cancer\n7. Child-Pugh class A\n8. Eastern Cooperative Oncology Group (ECOG) performance status of 1 or less\n9. Patients without serious dysfunction of major organs, as indicated by blood tests conducted within one month of study enrollment\n\n   1. Leukocytes ≥ 2,500\u002FµL and ≤ 12,000\u002FµL\n   2. Absolute neutrophil count ≥ 1,500\u002Fmm\\^3\n   3. Hemoglobin ≥ 8.0 g\u002FdL (transfusions allowed to meet this criterion)\n   4. Total bilirubin ≤ 3.0 mg\u002FdL\n   5. Platelets ≥ 50,000\u002FµL\n   6. For patients not on anticoagulants, INR ≤ 2.0\n   7. AST ≤ 200 IU\u002FL (i.e., ≤ 5X upper normal limit)\n   8. ALT ≤ 200 IU\u002FL (i.e., ≤ 5X upper normal limit)\n   9. ALP ≤ 575 IU\u002FL (i.e., ≤ 5X upper normal limit)\n   10. Creatinine ≤ 2.0 mg\u002FdL\n10. Patients with a life expectancy of more than 3 months\n11. Patients who have fully understood the clinical trial and given written consent\n12. Female patients of childbearing age confirmed not to be pregnant\n\nExclusion Criteria:\n\n1. Patients unsuitable for ablative radioembolization as per the pre-test with macro-aggregated albumin labeled with technetium-99 (99mTc-MAA) for radioembolization.\n\n   1. Cases where, according to multi-compartment Medical Internal Radiation Dose method, delivering 205 Gy of radiation to the tumor exceeds an estimated lung dose of 25 Gy.\n   2. Cases with severe hepatic artery-portal vein shunting leading to expected irradiation of the non-tumorous opposite lobe.\n2. Patients whose volume of non-tumorous liver not included in the treatment area is less than 30% of the total non-tumorous liver volume.\n3. Patients with hepatic vein or bile duct invasion as seen on dynamic contrast-enhanced CT or MRI.\n4. Patients scheduled to use immunotherapy regardless of the response to radioembolization.\n5. Patients who had active cancer within two years prior to joining the clinical trial.\n6. Patients who have undergone surgery or procedures related to the bile duct.\n7. Pregnant or breastfeeding women.",{"count":83,"type":21},[57],"The RESOLVE trial, an open-label, single-arm, multi-center study, aims to assess the efficacy and safety of ablative radioembolization using TheraSphere Yttrium-90 microspheres. This trial specifically targets patients diagnosed with hepatocellular carcinoma accompanied by localized portal vein tumor thrombosis (Vp1-Vp3) and who maintain good liver function.",[87],[63,61,108],"Portal vein tumor thrombosis",{"date":35,"type":36},{"date":111,"type":36},"2023-11-20",{"date":113,"type":21},"2027-11-30",{"name":42,"class":43},5,{"id":117,"slug":118,"hasResults":12,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":12,"sex":17,"minAge":124,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":22,"phases":128,"briefSummary":129,"conditions":130,"keywords":132,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":143},"100652177","comparison-of-office-and-cuffless-ambulatory-blood-pressure-guided-management-in-patients-with-hypertension-100652177","NCT07770477","Comparison of Office and Cuffless Ambulatory Blood Pressure-Guided Management in Patients With Hypertension","Comparison of Clinical Outcomes Between Office and Cuffless Ambulatory Blood Pressure-guided Management in Patients With Hypertension","CUFFLESS","Inclusion Criteria:\n\n* 24 hour mean SBP ≥ 130 mmHg by cuffless ambulatory BP monitor\n* aged ≥30 and \\\u003C80 years\n* voluntarily decide to participate in this clinical trial and provide written informed consent after being adequately informed.\n* willing and able to comply with the requirements of the study protocol\n\nExclusion Criteria:\n\n* Did not agree with this clinical trial and did not provide informed consent\n* Office SBP ≥ 190 mmHg, or diastolic BP (DBP) \\\u003C 60 mmHg.\n* Diagnosed secondary hypertension.\n* Hospitalization for stroke, myocardial infarction (MI) or unstable angina within the last 6 months\n* Coronary revascularization (percutaneous coronary intervention \\[PCI\\] or coronary artery bypass grafting \\[CABG\\]) within the last 12 months.\n* Planned to perform coronary revascularization (PCI or CABG) in the next 12 months.\n* History of sustained atrial fibrillation (AF) or ventricular arrhythmias at entry influencing the BP measurement of ring-type cuffless BP monitoring device.\n* Severe valvular disease or valvular disease likely to require surgery or percutaneous valve replacement during the trial.\n* Underlying heart disease: Hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), rheumatic heart disease or congenital heart disease\n* Uncontrolled diabetes mellitus (serum fasting glucose \\> 200 mg\u002FdL or glycated hemoglobin \\[HbA1c\\] \\>8%).\n* Severe liver dysfunction (alanine aminotransferase \\[ALT\\] \\> 3 times the upper limit of normal (ULN) value).\n* Severe renal dysfunction (end stage renal disease \\[ESRD\\] on dialysis or estimated glomerular filtration rate \\[eGFR\\] \\\u003C30 ml\u002Fmin\u002F1.73m², or serum creatinine \\>2.5 mg\u002FdL.\n* Malignancy history within 5 years.\n* Severe cognitive impairment or mental disorders.\n* Participating in other clinical trials other than observation registry","30 Years","79 Years",{"count":127,"type":21},3000,[24],"Hypertension is a major risk factor for cardiovascular and cerebrovascular diseases, including stroke and myocardial infarction. Blood pressure (BP) fluctuates throughout the day in response to physical activity, emotional states, and sleep. However, hypertension diagnosis and management are commonly based on BP measurements obtained in the clinic or at home, which may not fully reflect these variations. This can contribute to discrepancies between office and out-of-office BP, including white-coat and masked hypertension.\n\nAmbulatory blood pressure monitoring (ABPM) provides information on BP throughout daily activities and sleep, but conventional cuff-based ABPM may be limited by discomfort, accessibility, and logistical challenges. Recently, cuffless wearable devices have enabled repeated BP monitoring without the use of a conventional inflatable cuff.\n\nThe CUFFLESS study is a multicenter, prospective, randomized controlled trial comparing two strategies for the management of hypertension: cuffless ambulatory BP-guided management and conventional office BP-guided management. Participants will be randomly assigned to either management strategy and followed for clinical outcomes. The primary objective is to determine whether hypertension management guided by cuffless ambulatory BP monitoring reduces the occurrence of cardiovascular events compared with management guided by conventional office BP measurements.",[131],"Hypertension",[133,134],"Cuffless Blood Pressure Monitoring","Ambulatory Blood Pressure Monitoring","NOT_YET_RECRUITING","2026-08-17",{"date":65,"type":36},{"date":139,"type":21},"2026-08-24",{"date":141,"type":21},"2036-12-31",{"name":42,"class":43},9,{"id":145,"slug":146,"hasResults":12,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":154,"phases":4,"briefSummary":155,"conditions":156,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":167},"100596279","streamlining-radioembolization-for-ccc-and-metastatic-liver-cancer-100596279","NCT07043387","Streamlining Radioembolization for CCC and Metastatic Liver Cancer","Streamlining Radioembolization for Cholangiocarcinoma or Metastatic Liver Cancer ≤ 7 cm : Multicenter Prospective Registry Study","ISTAR-03","Inclusion Criteria:\n\n* Adult aged 19 and over\n\n  * metastatic liver cancer or cholangiocarcinoma\n\n    * the diameter of the largest tumor ≤ 7cm, tumor number 5 or less\n\n      * FLR volume \\> 30% of total non-tumorous liver volume\n\n        * Dysmorphic intratumoral vessel : absent, if present, 3mm or thinner ⑥ Child-Pugh class A\n\n          * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 ⑧ No major organ dysfunction according to blood test performed within two months of study enrollment A. Leukocytes ≥ 1,000\u002FµL and ≤ 20,000\u002FµL B. Hemoglobin ≥ 6.0 g\u002FdL (transfusion allowed to meet this criterion) C. Total bilirubin ≤ 2.0 mg\u002FdL D. Platelet ≥ 40,000\u002FµL E. International normalized ratio (INR) ≤ 2.0 for patients not taking anticoagulants F. Aspartate transaminase (AST) ≤ 800 IU\u002FL (i.e., ≤ 20X upper normal limit) G. Alanine transaminase (ALT) ≤ 800 IU\u002FL (i.e., ≤ 20X upper normal limit) H. Creatinine ≤ 2.5 mg\u002FdL (If patients is undergoing hemodialysis, no limit of creatinine) ⑨ Patients with a life expectancy of more than 3 months ⑩ For women of childbearing age, a negative serum pregnancy test. ⑪ Patients who have adequately understood the clinical trial and consented in writing\n\nExclusion Criteria:\n\n* hepatic vein invasion on dynamic computed tomography (CT) or magnetic resonance imaging (MRI)\n* Hepatic vein enhancement on arterial phase CT\u002FMRI\n* dysmorphic intratumoral vessel \\> 3mm on arterial phase CT\u002FMRI\n* TIPS is present\n* Lobar portal vein enhancement on arterial phase CT\u002FMRI due to AP shunt\n* main portal vein tumor thrombosis\n* Cases where the operator judges that the occurrence of even mild radiation pneumonitis could be fatal, based on marked emphysema or interstitial lung disease findings on chest CT\n* biliary stent or bilioenteric anastomosis\n* History of severe allergy of intolerance to contrast agents\n* Contraindication to angiography or selective visceral catheterization",{"count":153,"type":21},60,"OBSERVATIONAL","TARE uses radioactive microspheres (20-60 μm), which are trapped in tumors due to abnormal vasculature, while normal liver sinusoids (≤15 μm) prevent their passage. However, some microspheres may drain into hepatic veins and reach the lungs, risking radiation pneumonitis. Pre-procedural evaluation with angiography and nuclear imaging (MAA scan with SPECT\u002FCT) is required to calculate lung shunt fraction (LSF). TARE is contraindicated if LSF \\>20%, and may be used with caution if LSF is 10-20%.\n\nFindings associated with high LSF include large tumors, hepatic vein invasion, TIPS, and dysmorphic intratumoral vessels. In contrast, small or medium sized (\\\u003C7 cm) cholangiocarcinoma or metastatic liver cancers without hepatic vein invasion or dysmorphic vessels show consistently low LSF (\\\u003C5%). Over 10 years at SNUH, no cases of radiation pneumonitis have been observed in such patients. Therefore, \"streamlining TARE\" omits pre-procedural nuclear imaging for this group to reduce procedural delays, reserving nuclear imaging for patients who need it most.\n\nSIR-Spheres (SIRTEX) facilitate single-session TARE as they are provided in a bulk vial, unlike TheraSphere which requires advance preparation based on dosimetry.\n\nProtocol Overview :\n\nProcedure: Same-day angiography, cone-beam CT, and TARE using SIR-Spheres.\n\nDosimetry: Lung shunt fraction is assumed as 5%, estimated lung dose is capped at 10 Gy.\n\nTumor dose goal: 80\\~400 Gy (around 250Gy)(single-compartment MIRD), or 300 \\~ 1000 Gy (multi-compartment MIRD). minimal tumor dose by partition dosimetry : 100Gy\n\nSoftware: Simplicit90Y for planning, Y90 PET\u002FCT the next day for post-treatment dosimetry.\n\nFollow-up: 1 year; additional treatments follow institutional guidelines.\n\nThis streamlined approach maximizes efficiency while maintaining safety in selected patients.",[157,158,159],"Metastatic Colorectal Carcinoma (mCRC)","Metastatic Liver Cancer","Cholangiocarcinoma","2026-08-16",{"date":65,"type":36},{"date":163,"type":36},"2025-06-22",{"date":165,"type":21},"2029-06-30",{"name":42,"class":43},4,{"id":169,"slug":170,"hasResults":12,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":154,"phases":4,"briefSummary":178,"conditions":179,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":180,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":115},"100591345","streamlining-radioembolization-for-small-hcc-100591345","NCT06979219","Streamlining Radioembolization for Small HCC","Streamlining Radioembolization for HCC ≤ 5 cm With Y90 Resin Microspheres : Multicenter Prospective Registry Study","ISTAR-02","Inclusion Criteria:\n\n* adults aged \\>18 years\n* Patients diagnosed with hepatocellular carcinoma histologically and\u002For radiologically (LI-RADS 4 or 5)\n* hepatocellular carcinoma 5cm or smaller\n* Tumor number is 3 or smaller\n* Dysmorphic intratumoral vessel is absent or smaller than 3 mm\n* Child-Pugh class A\n* ECOG 0 or 1\n* the following lab should be met. A. Leukocytes ≥ 1,000\u002FµL and ≤ 20,000\u002FµL B. Hemoglobin ≥ 6.0 g\u002FdL (transfusion allowed to meet this criterion) C. Total bilirubin ≤ 2.0 mg\u002FdL D. Platelet ≥ 40,000\u002FµL E. International normalized ratio (INR) ≤ 2.0 for patients not taking anticoagulants F. Aspartate transaminase (AST) ≤ 800 IU\u002FL (i.e., ≤ 20X upper normal limit) G. Alanine transaminase (ALT) ≤ 800 IU\u002FL (i.e., ≤ 20X upper normal limit) H. Creatinine ≤ 2.5 mg\u002FdL (if patient is receiving hemodialysis, no upper limit of creatinine)\n* Patients with a life expectancy of \\>3 mo\n* Patients who have adequately understood the clinical trial and consented in writing\n* Nonpregnant women of childbearing potential\n\nExclusion Criteria:\n\n1. Hepatic vein invasion on CT\u002FMRI\n2. Marked enhancement of portal vein or hepatic vein on arterial phase of CT\u002FMRI\n3. Dysmorphic intratumoral vessel ≥3mm\n4. Patient with transjugular intrahepatic portosystemic shunt\n5. Patient with bilioenteric anastomosis or biliary stent\n6. Patient with centrilobular emphysema or interstitial lung disease\n7. main portal vein invasion",{"count":177,"type":21},146,"In patients who has no sign suggesting high lung shunt fraction (TIPS, hepatic vein invasion, hepatic vein enhancement on arterial phase, dysmorphic intratumoral vessel, tumor size \\\u003C 5cm), radioembolization is performed without MAA scan with SIR-Spheres. This prospective registry will prove that the selection criteria is accurate and streamlining radioembolization is feasible and safe.",[60],{"date":65,"type":36},{"date":182,"type":36},"2025-06-10",{"date":184,"type":21},"2029-12-31",{"name":42,"class":43},{"id":187,"slug":188,"hasResults":12,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":194,"targetDuration":196,"studyType":154,"phases":4,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":199,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":203,"locationsCount":167},"100588675","same-day-radioembolization-for-large-hcc-100588675","NCT06944483","Same-day Radioembolization for Large HCC","Same-day Radioembolization for Large HCC (>5cm) With Y90 Resin Microspheres : Multicenter Prospective Registry Study","ISTAR-01","Inclusion Criteria:\n\n* Patients diagnosed with hepatocellular carcinoma histologically and\u002For radiologically (LI-RADS 4 or 5)\n* hepatocellular carcinoma 5cm or larger\n* dysmorphic intratumoral vessels 3mm or smaller\n* Child-Pugh class A\n* ECOG 0 or 1\n* the following lab should be met. A. Leukocytes ≥ 1,000\u002FµL and ≤ 20,000\u002FµL B. Hemoglobin ≥ 6.0 g\u002FdL (transfusion allowed to meet this criterion) C. Total bilirubin ≤ 2.0 mg\u002FdL D. Platelet ≥ 40,000\u002FµL E. International normalized ratio (INR) ≤ 2.0 for patients not taking anticoagulants F. Aspartate transaminase (AST) ≤ 800 IU\u002FL (i.e., ≤ 20X upper normal limit) G. Alanine transaminase (ALT) ≤ 800 IU\u002FL (i.e., ≤ 20X upper normal limit) H. Creatinine ≤ 2.5 mg\u002FdL (if patient is receiving hemodialysis, no upper limit of creatinine)\n* Patients with a life expectancy of \\>3 mo\n* Patients who have adequately understood the clinical trial and consented in writing\n* Nonpregnant women of childbearing potential\n\nExclusion Criteria:\n\n* hepatic vein invasion on CT\u002FMRI\n* Marked enhancement of portal vein or hepatic vein on arterial phase of CT\u002FMRII\n* TIPS\n* dysmorphic intratumoral vessels \\> 3mm\n* main portal vein invasion\n* significant COPD or interstitial lung disease\n* biliary stent or enterobiliary anastomosis",{"count":195,"type":21},138,"12 Months","In patients who has no sign suggesting high lung shunt fraction (TIPS, hepatic vein invasion, hepatic vein enhancement on arterial phase, dysmorphic intratumoral vessel), planning angiography, MAA scan, and radioembolization are performed in a single day with SIR-Spheres. This prospective registry will prove that the selection criteria is accurate and same-day radioembolization is feasible and safe.",[60],{"date":65,"type":36},{"date":201,"type":36},"2025-04-25",{"date":184,"type":21},{"name":42,"class":43},{"id":205,"slug":206,"hasResults":12,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":211,"targetDuration":212,"studyType":154,"phases":4,"briefSummary":213,"conditions":214,"keywords":218,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":44},"100652226","can-a-pain-monitor-predict-when-postoperative-intensive-care-unit-patients-are-ready-to-breathe-on-their-own-a-pilot-study-100652226","NCT07771101","Can a Pain Monitor Predict When Postoperative Intensive Care Unit Patients Are Ready to Breathe on Their Own? A Pilot Study","Association Between Early Autonomic Dysfunction Measured by the Analgesia Nociception Index (ANI) and Prolonged Mechanical Ventilation in Postoperative ICU Patients","Inclusion Criteria:\n\n* Age 18 years or older\n* Admitted to the surgical intensive care unit (ICU) after surgery\n* Currently on a breathing machine (mechanical ventilation) through a tube in the airway\n* Receiving dexmedetomidine as the main sedative medication, with a stable, predefined level of sedation\n* Participant or their legal representative agrees to take part in the study\n\nExclusion Criteria:\n\n* Permanent irregular heart rhythm (atrial fibrillation or atrial flutter)\n* Complete heart block or a heart rhythm that is fully controlled by a pacemaker\n* Already has a tracheostomy (a breathing tube placed through the neck)\n* A decision has already been made at ICU admission to withhold or withdraw life-sustaining treatment\n* Deeply sedated without receiving any sedative medication, suggesting the low alertness may be due to a brain-related problem rather than medication",{"count":20,"type":21},"28 Days","The goal of this observational study is to learn if a chest monitor that tracks heart rhythm can help predict whether adults on a breathing machine after surgery will be able to breathe on their own once the breathing tube is removed. It is being done in adults recovering from surgery in the intensive care unit (ICU).\n\nThe main questions it aims to answer are:\n\nCan heart rhythm patterns, measured soon after ICU admission and during a breathing test, show whether a patient is likely to breathe well without the machine? Do these patterns change in a helpful way when the breathing tube is removed?\n\nParticipants will:\n\nHave soft, sticky patches placed on their chest, similar to those used for a regular heart monitor Have their heart rhythm recorded for 5 minutes at four times: soon after ICU admission, before a breathing test, during the breathing test, and right after the breathing tube is removed Continue to receive their usual ICU care; doctors will not see the monitor's readings, so these readings will not affect any treatment decisions",[215,216,217],"Ventilator Weaning","Airway Extubation","Respiration, Artificial",[219,220,221,222,223,224,225],"Heart Rate Variability","Autonomic Nervous System","Intensive Care Units","Analgesia Nociception Index","Postoperative Care","Spontaneous Breathing Trial","Critical Illness","2026-08-13",{"date":65,"type":36},{"date":229,"type":36},"2026-08-11",{"date":231,"type":21},"2027-08-12",{"name":42,"class":43},{"id":234,"slug":235,"hasResults":12,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":240,"sex":17,"minAge":53,"maxAge":18,"enrollmentInfo":241,"targetDuration":4,"studyType":22,"phases":242,"briefSummary":243,"conditions":244,"keywords":248,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":4},"100651223","effects-of-home-based-transcranial-direct-current-stimulation-on-appetite-100651223","NCT07757438","Effects of Home-Based Transcranial Direct Current Stimulation on Appetite","Neurophysiological Effects of Transcranial Direct Current Stimulation on Appetite: Randomized, Placebo-Controlled, Double-Blind, Parallel-Design","Inclusion Criteria:\n\n* Adults aged 19 to 65 years\n* Binge Eating Scale (BES) score ≥18\n* BMI ≥18.5 kg\u002Fm²\n* No significant weight loss or lifestyle changes during the previous 3 months\n* Stable chronic medical conditions (e.g., hypertension, diabetes, dyslipidemia) are allowed\n* Able to use an Android smartphone compatible with the study application (including a study phone if provided)\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Unable to understand the study procedures or provide informed consent\n* Implanted pacemaker, implantable cardioverter-defibrillator, deep brain stimulator, cochlear implant, coronary stent, or other implanted metallic medical devices (dental implants and joint prostheses are allowed)\n* Diagnosis or treatment for a psychiatric or neurological disorder within the previous 3 months\n* Use of medications affecting appetite or body weight within the previous month\n* Use of medications affecting eating behavior or mood within the previous month\n* Pregnant or breastfeeding\n* Any medical condition judged by the investigator to interfere with study participation or interpretation of study results",true,{"count":55,"type":21},[24],"This randomized, placebo-controlled, double-blind, parallel-design study aims to evaluate the neurophysiological effects of home-based transcranial direct current stimulation (tDCS) on appetite in adults with binge eating tendencies.\n\nParticipants will be randomly assigned to either an active tDCS group or a sham stimulation group. After baseline assessments, participants will self-administer home-based tDCS twice daily for 4 weeks using a wearable wellness device. Appetite, eating behavior, body composition, dietary intake, and psychological outcomes will be assessed throughout the study to evaluate both the acute and chronic effects of repeated tDCS.",[245,246,247],"Appetite","Binge Eating Behaviour","Food Cravings",[249,250,245,251,252,253,254,255],"Transcranial Direct Current Stimulation","tDCS","Food Craving","Binge Eating","Eating Behavior","Home-based Intervention","Neuromodulation","2026-08-07",{"date":229,"type":36},{"date":259,"type":21},"2026-08-15",{"date":261,"type":21},"2027-04-30",{"name":42,"class":43},{"id":264,"slug":265,"hasResults":12,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":271,"enrollmentInfo":272,"targetDuration":4,"studyType":22,"phases":274,"briefSummary":276,"conditions":277,"keywords":279,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":290},"100480292","platform-study-of-circulating-tumor-dna-directed-adjuvant-chemotherapy-in-colon-cancer-kcsg-co22-12-100480292","NCT05534087","Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)","A Randomized Controlled Phase III Trial of Treatment Intensification in Stage II-III Colon Cancer Patients With Positive MRD During Adjuvant Chemotherapy","CLAUDIA","Inclusion Criteria:\n\n1. Patients who willingly consented and signed the informed consent form to participate in the study\n2. Age range of 19 to 75 years\n3. Adenocarcinoma of colon confirmed by histology\n4. Patients with stage II-III colon cancer as defined by the American Joint Committee on Cancer's eighth edition (Stage II cancer is limited to patients who are at a high risk, with more than one risk factor for recurrence.)\n5. Patients who have completed the sixth cycle of FOLFOX or the fourth cycle of CAPOX adjuvant chemotherapy for colon cancer following radical resection (R0 resection)\n6. A ctDNA test performed 3 to 6 weeks after surgery reveals a positive MRD\n7. ECOG performance scale of 0-1 (only 1 is allowed for 70-75 years old)\n8. Adequate bone marrow function \\[ANC ≥1,300\u002FLL, platelets ≥75,000\u002FLL, hemoglobin ≥8.0g\u002FdL (may be eligible in study if intermittent transfusion is required)\\]\n9. Appropriate liver function (total bilirubin ≤1.5xULN, AST and ALT ≤3xULN)\n10. Appropriate renal function (serum creatine ≤1.5xULN, renal clearance rate ≥50 ml\u002Fmin)\n11. Patients who are deemed to understand the study protocol and are willing to participate in the trial until it is completed\n\nExclusion Criteria:\n\n1. Pregnant or lactating women\n2. Pregnant women who had a positive pregnancy test at the time of the baseline examination (postmenopausal women must be amenable for at least 12 months to be considered non-fertility)\n3. Sexually active men and women of reproductive age who are unwilling to use contraception throughout the study treatment and for a period of 6 months (female) or 3 months (male) following the discontinuation of study treatment\n4. Clinically significant heart condition \\[unstable angina requiring medication, symptomatic coronary artery disease, congestive heart failure, or significant heart arrhythmia above NYHA II, or acute coronary syndrome, including myocardial infarction within the last 6 months\\]\n5. Active viral infections such as HIV (However, HBV carriers may enroll if their HBV DNA titer is less than 20,000 IU\u002Fml, and antiviral drugs for hepatitis B may be administered prophylactically at the investigator's discretion)\n6. Significant uncontrolled infections or other uncontrolled comorbidities\n7. Symptomatic inflammatory bowel disease\n8. Allogeneic transplantation history necessitating immunosuppressive therapy\n9. A history of other malignancies identified within the last three years, except for completed removed basal cell carcinoma of the skin, completely removed cervical epithelial carcinoma, and thyroid cancer that has been treated, including surgery\n10. Recurrent or residual disease identified clinically or radiographically\n11. Previous history of irinotecan treatment\n12. Polyposis including familial adenomatous polyps\n13. Two or more colon or rectal cancers with a pathologic stage greater than II that were detected concurrently or within the last three years\n14. When the investigator determines that the subjects' safety may be jeopardized during the study because of other serious or unstable pre-existing medical or mental conditions\n15. Prior clinical trial participation and usage of investigational drugs or devices following radical resection of colon cancer\n16. Patients with peripheral neuropathy who have a CTCAE v5 grade 3 or higher functional disability (corresponds to \"severe symptoms, limiting self-care activity of daily living\" according to CTCAE v5 criteria)\n17. Previous anaphylactic reaction or severe and unexpected reactions to fluoropyrimidines or platinum\n18. Gilbert's syndrome, dehydro-pyridine dehydrogenase (DPD) deficiency, or homozygous UGT1A1\\*28 alleles","75 Years",{"count":273,"type":21},236,[275],"PHASE3","This study is a prospective, open-label, randomized phase 3 clinical trial. It aims to investigate if the early introduction of intensified chemotherapy (3 months of modified FOLFIRINOX) improves the 3-year disease-free survival rate compared to standard treatment (FOLFOX\u002FCAPOX for an additional three months to complete six months of standard adjuvant chemotherapy) in patients with stage 2-3 colon cancer in whom ctDNA MRD in the part 1 study remained positive during adjuvant FOLFOX\u002FCAPOX chemotherapy",[278],"Colon Cancer",[280,281],"Minimal residual disease","Intensified chemotherapy","2026-08-05",{"date":284,"type":36},"2026-08-10",{"date":286,"type":36},"2022-12-15",{"date":288,"type":21},"2030-09-30",{"name":42,"class":43},13,{"id":292,"slug":293,"hasResults":12,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":4,"eligibilityCriteria":297,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":298,"targetDuration":4,"studyType":22,"phases":300,"briefSummary":301,"conditions":302,"keywords":4,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":307,"completionDateStruct":308,"leadSponsor":310,"locationsCount":4},"100650825","local-anesthetic-infiltration-for-pain-control-after-orthopedic-wide-excision-100650825","NCT07753629","Local Anesthetic Infiltration for Pain Control After Orthopedic Wide Excision","Analgesic Effect of Subcutaneous Local Infiltration Anesthesia Before Skin Closure on Postoperative Pain in Patients Undergoing Orthopedic Wide Excision: A Prospective Double-Blind Randomized Controlled Trial","Inclusion Criteria:\n\n* Scheduled to undergo elective orthopedic wide excision surgery under general anesthesia\n* American Society of Anesthesiologists (ASA) Physical Status Classification 1, 2, or 3\n* Age 19 years or older\n\nExclusion Criteria:\n\n* Unwilling to provide informed consent\n* History of allergy to local anesthetics\n* History of chronic pain\n* Use of opioid analgesics within 24 hours before surgery\n* Active infection at the surgical site",{"count":299,"type":21},58,[24],"This study evaluates whether injecting a local anesthetic mixture (ropivacaine, morphine, ketorolac, and epinephrine) under the skin at the incision site before wound closure reduces pain after orthopedic wide excision surgery for bone or soft tissue tumors. Participants will be randomly assigned to receive either the local anesthetic mixture or a saline control injection. Neither participants nor the study team assessing outcomes will know which treatment was given. The main goal is to determine whether this injection reduces the amount of opioid pain medication needed during the first 24 hours after surgery. The study will also assess pain scores, nausea and vomiting, and quality of recovery.",[303,304],"Wide Excision","Postoperative Pain","2026-08-03",{"date":256,"type":36},{"date":256,"type":21},{"date":309,"type":21},"2028-07-31",{"name":42,"class":43},{"id":312,"slug":313,"hasResults":12,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":317,"eligibilityCriteria":318,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":319,"targetDuration":4,"studyType":22,"phases":321,"briefSummary":322,"conditions":323,"keywords":327,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":333,"completionDateStruct":334,"leadSponsor":335,"locationsCount":4},"100649178","distal-versus-conventional-radial-arterial-catheterization-for-arterial-waveform-stability-100649178","NCT07732296","Distal Versus Conventional Radial Arterial Catheterization for Arterial Waveform Stability","Distal Versus Conventional Radial Arterial Catheterization for Arterial Waveform Stability During Arm-Tucked Robotic Urologic Surgery: A Prospective Randomized Controlled Study","DRA-stability","Inclusion Criteria:\n\n* Adults aged 19 years or older\n* Scheduled to undergo robot-assisted urologic surgery under general anesthesia\n* Scheduled to have both arms positioned alongside the body in an arm-tucked position during surgery\n* Considered by the attending anesthesiologist to require intraoperative invasive arterial blood pressure monitoring\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Refusal to participate or inability to provide written informed consent\n* Emergency surgery\n* Pregnancy or breastfeeding\n* Lack of decision-making capacity requiring consent from a legally authorized representative\n* Presence of an arteriovenous fistula for dialysis or unsuitable bilateral radial artery access\n* Infection, burn, trauma, surgical scar, or severe skin lesion at the intended puncture site\n* Suspected hand perfusion impairment, including radial artery occlusion, absent radial pulse, severe peripheral vascular disease, or Raynaud phenomenon\n* Severe coagulopathy or uncorrected bleeding tendency for which radial arterial catheterization is considered inappropriate\n* Any condition for which the attending anesthesiologist considers study participation inappropriate for participant safety",{"count":320,"type":21},70,[24],"During robot-assisted urologic surgery, both arms are often placed alongside the body and covered by surgical drapes. This position can make the arterial catheter difficult to access during surgery. A conventional radial arterial catheter placed at the wrist may become compressed or bent because of wrist position or arm fixation, which can cause an inaccurate or dampened arterial blood pressure waveform. A distal radial arterial catheter may be less affected by wrist movement or pressure on the forearm.\n\nThis single-center randomized study will include 70 adults undergoing robot-assisted urologic surgery under general anesthesia who require invasive arterial blood pressure monitoring. Participants will be randomly assigned in a 1:1 ratio to ultrasound-guided conventional radial arterial catheterization at the wrist or distal radial arterial catheterization near the anatomical snuffbox or back of the hand.\n\nThe main purpose of the study is to determine whether distal radial arterial catheterization reduces clinically significant arterial catheter dysfunction requiring troubleshooting or rescue treatment while the arms are tucked. The study will also compare catheter insertion success, first-attempt success, insertion time, episodes of dampened or lost arterial pressure waveforms, difficulty obtaining arterial blood samples, need for catheter replacement or another arterial access site, and catheter-related complications.",[324,325,326],"Intraoperative Arterial Blood Pressure Monitoring","Arterial Catheter Dysfunction","Robotic Urologic Surgery",[328,329,330],"Distal Radial Artery","Radial Arterial Catheterization","Arterial Waveform Damping","2026-08-02",{"date":282,"type":36},{"date":282,"type":21},{"date":40,"type":21},{"name":42,"class":43},{"id":337,"slug":338,"hasResults":12,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":4,"eligibilityCriteria":342,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":343,"targetDuration":4,"studyType":22,"phases":345,"briefSummary":347,"conditions":348,"keywords":350,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":167},"100624542","phase-4-hydroxyethyl-starch-versus-crystalloid-and-postoperative-major-adverse-kidney-complications-100624542","NCT07410988","Hydroxyethyl Starch Versus Crystalloid and Postoperative Major Adverse Kidney Complications","Effect of 130\u002F0.4 Hydroxyethyl Starch vs. Balanced Crystalloid for Intraoperative Fluid Therapy on Major Composite Renal Outcomes After Cardiac Surgery: a Multicenter, Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients aged 19 years or older scheduled for coronary artery bypass grafting (CABG), heart valve surgery, and\u002For thoracic aortic surgery\n\nExclusion Criteria:\n\n1. Emergency surgery;\n2. Planned implantation of a durable left ventricular assist device;\n3. History of starch allergy or hypersensitivity;\n4. History of kidney transplantation;\n5. Preoperative end-stage renal disease (ESRD) or requirement for renal replacement therapy (RRT);\n6. Preoperative glomerular filtration rate \\\u003C 30 mL\u002Fmin\u002F1.73 m2;\n7. Planned intraoperative and postoperative RRT;\n8. Preoperative use of mechanical circulatory support devices (e.g., intra-aortic balloon pump, extracorporeal membrane oxygenation, etc.);\n9. Significant clinical coagulopathy (e.g., active bleeding disorder or thrombocytopenia with a platelet count \\\u003C100,000\u002FµL);\n10. Active infective endocarditis.",{"count":344,"type":21},1292,[346],"PHASE4","This trial aims to compare two intraoperative fluids, namely hydroxyethyl starch (HES) and balanced crystalloids in terms of major adverse kidney events after cardiac surgery. Indications for the study fluids administarion include preload augmentation and intravascular volume replacement during cardiac surgery.",[349],"Cardiac Surgery",[351],"hydroxyethyl starch","2026-07-29",{"date":354,"type":36},"2026-07-30",{"date":356,"type":36},"2026-06-22",{"date":358,"type":21},"2029-07-31",{"name":42,"class":43},{"id":361,"slug":362,"hasResults":12,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":4,"eligibilityCriteria":366,"healthyVolunteers":12,"sex":17,"minAge":367,"maxAge":81,"enrollmentInfo":368,"targetDuration":4,"studyType":22,"phases":370,"briefSummary":371,"conditions":372,"keywords":374,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":386,"locationsCount":44},"100650015","remote-exercise-program-for-pediatric-icu-survivors-100650015","NCT07741942","Remote Exercise Program for Pediatric ICU Survivors","Feasibility Study of a Remote Exercise Intervention Program for Preventing Post-Intensive Care Syndrome in Pediatric Critical Illness Survivors","Inclusion Criteria:\n\n* Age 3 to 18 years.\n* Discharged from the pediatric intensive care unit (PICU) after at least 48 hours of treatment.\n* Has not recovered to the pre-PICU level of physical function (walking and mobility), confirmed using the Pediatric Overall Performance Category Scale (POPC) and the Gross Motor Function Classification System Family Report Questionnaire (GMFCS Family Report).\n* Has sufficient cognitive and physical ability to understand and participate in the home-based exercise intervention.\n* Able to maintain adequate attention for exercise training, assessed using the Richmond Agitation-Sedation Scale (RASS) and age-appropriate delirium assessment (psCAM-ICU or pCAM-ICU), when applicable.\n* Written informed consent provided by the parent or legal guardian.\n\nExclusion Criteria:\n\n* Newly developed neuromuscular disease after PICU admission that prevents participation in the video-based exercise program without therapist assistance.\n* Medical conditions, indwelling catheters, or implanted medical devices requiring restriction of limb movement.\n* Language or cognitive impairment that prevents understanding of the video-based exercise program.\n* Uncontrolled hypertension, arrhythmia, persistent fever due to infection, or any condition making exercise unsafe.\n* Declines to participate in the study.","3 Years",{"count":369,"type":21},10,[24],"This pilot clinical trial aims to evaluate the feasibility and safety of a remote exercise intervention program designed to prevent pediatric post-intensive care syndrome (PICS-p) in children discharged from the pediatric intensive care unit (PICU). Children aged 3 to 18 years who received intensive care for at least 48 hours and have not recovered to their pre-admission functional status will participate in an individualized home-based exercise program for 12 weeks. The intervention includes remotely supervised exercise sessions, prescribed self-exercise, and weekly monitoring using videoconferencing. Study assessments will be performed at baseline, immediately before intervention initiation, monthly during the 12-week intervention, and 1 month after completion of the intervention to evaluate feasibility, safety, functional recovery, and maintenance of treatment effects.",[373,225],"Pediatric Post-Intensive Care Syndrome",[375,376,377,378,379],"Pediatric intensive care unit","Post-intensive care syndrome","Remote exercise","Telerehabilitation","Pediatric rehabilitation","2026-07-28",{"date":305,"type":36},{"date":383,"type":21},"2026-09",{"date":385,"type":21},"2027-03",{"name":42,"class":43},{"id":388,"slug":389,"hasResults":12,"nctId":390,"briefTitle":391,"officialTitle":392,"acronym":393,"eligibilityCriteria":394,"healthyVolunteers":12,"sex":17,"minAge":395,"maxAge":4,"enrollmentInfo":396,"targetDuration":4,"studyType":22,"phases":398,"briefSummary":399,"conditions":400,"keywords":404,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":412,"completionDateStruct":413,"leadSponsor":415,"locationsCount":44},"100649415","phase-4-angiotensin-receptor-blocker-after-tavr-in-severe-aortic-stenosis-with-left-ventricular-hypertrophy-arbitar-100649415","NCT07735130","Angiotensin Receptor Blocker After TAVR in Severe Aortic Stenosis With Left Ventricular Hypertrophy (ARBITAR)","Angiotensin Receptor Blockade In Patients After Transcatheter Aortic Valve Replacement for Severe Aortic Stenosis With Left Ventricular Hypertrophy (ARBITAR) Trial","ARBITAR","Inclusion Criteria:\n\n* Male or female aged 40 years or older\n* Symptomatic severe aortic stenosis (AS) with left ventricular hypertrophy (LVH) who successfully underwent transcatheter aortic valve replacement (TAVR) within the prior 30 days, including native-valve or valve-in-valve TAVR\n\n  \\* Severe AS defined by at least one of the following: aortic valve area ≤1.0 cm²; aortic valve area index ≤0.6 cm²\u002Fm²; mean pressure gradient ≥40 mmHg; or maximal aortic valve velocity ≥4.0 m\u002Fsec\n\n  \\* LVH defined as left ventricular mass index \\>115 g\u002Fm² in men or \\>95 g\u002Fm² in women\n* Successful TAVR (technical success) meeting all VARC-3 criteria: survival; successful access, delivery, and retrieval of the device; correct positioning of a single prosthetic valve in the proper anatomic location; no additional surgery or procedure related to the device (excluding permanent pacemaker implantation) or to major vascular, access-site, or cardiac structural complications; and intended prosthetic valve performance (mean gradient \\\u003C20 mmHg, peak velocity \\\u003C3 m\u002Fs, Doppler velocity index ≥0.25, and less than moderate aortic regurgitation)\n* Left ventricular ejection fraction (LVEF) \\>40% before TAVR\n* Provided written informed consent to participate, either voluntarily or through a legal representative\n\nExclusion Criteria:\n\n* Hypotension (systolic blood pressure \\\u003C90 mmHg) or hemodynamic instability defined as a need for continuous intravenous vasopressor support at screening\n* Hyperkalemia (serum potassium \\>5.5 mmol\u002FL)\n* Bilateral renal artery stenosis without stent placement\n* Allergy, hypersensitivity, or prior intolerance to angiotensin receptor blockers\n* Pregnancy, breastfeeding, or planning to become pregnant\n* Estimated life expectancy of less than 2 years\n* Acute coronary syndrome diagnosed within the past 1 year\n* Estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73 m\\^2 by the CKD-EPI equation, or currently undergoing renal replacement therapy\n* Any other medical condition that, in the investigator's judgment, makes participation in the trial inappropriate","40 Years",{"count":397,"type":21},632,[346],"This is a multicenter, prospective, open-label, randomized, investigator-initiated trial evaluating whether angiotensin receptor blocker (ARB) therapy improves clinical outcomes in patients with severe aortic stenosis (AS) and left ventricular hypertrophy (LVH) who have undergone transcatheter aortic valve replacement (TAVR).\n\nSevere AS imposes chronic pressure overload on the left ventricle, leading to LVH as a compensatory response. While initially adaptive, sustained LVH promotes myocardial fibrosis, reduced ventricular compliance, and impaired cardiac function. LVH that persists after valve replacement is associated with increased morbidity and mortality, including a higher risk of heart failure. Blockade of the renin-angiotensin system (RAS) with angiotensin-converting enzyme inhibitors (ACEi) or ARBs has been proposed as a strategy to attenuate adverse left ventricular remodeling after valve replacement by inhibiting angiotensin II-mediated hypertrophic and fibrotic signaling. However, evidence in TAVR patients with LVH remains limited, and a small randomized trial of an ACEi reported drug discontinuation in approximately 10% of patients due to dry cough. The ARBITAR trial therefore evaluates the clinical efficacy of an ARB in this population.\n\nA total of 632 patients with symptomatic severe AS and LVH who have successfully undergone TAVR within the prior 30 days will be randomized 1:1 to receive an ARB (experimental group) or no ARB (control group), stratified by site and sex. Assigned treatment is continued for up to 24 months, with follow-up visits at 1, 6, 12, and 24 months. In the experimental group, the ARB (candesartan, losartan, or valsartan) is up-titrated toward a target dose. ACE inhibitors, direct renin inhibitors, and angiotensin receptor\u002Fneprilysin inhibitors are prohibited in both groups.\n\nThe primary endpoint is the composite of all-cause death or admission for heart failure over 2 years. Secondary endpoints include the individual components of the primary endpoint and other clinical events, as well as echocardiographic measures, NT-proBNP, NYHA functional class, and KCCQ-12 score. The primary analysis follows the intention-to-treat principle.",[401,402,403],"Transcatheter Aortic Valve Replacement (TAVR)","Left Ventricular Hypertrophy","Severe Aortic Stenosis",[405,406,407,408,409],"Severe aortic stenosis","Renin-angiotensin system blockade","Angiotensin receptor blocker","Transcatheter aortic valve replacement (TAVR)","Left ventricular hypertrophy","2026-07-26",{"date":352,"type":36},{"date":259,"type":21},{"date":414,"type":21},"2030-06-15",{"name":42,"class":43},{"id":417,"slug":418,"hasResults":12,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":4,"eligibilityCriteria":422,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":423,"enrollmentInfo":424,"targetDuration":4,"studyType":22,"phases":425,"briefSummary":426,"conditions":427,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":433,"completionDateStruct":435,"leadSponsor":437,"locationsCount":44},"100649186","effects-of-semaglutide-on-brain-dopamine-responses-to-food-cues-in-adults-with-obesity-and-food-addiction-tendencies-100649186","NCT07732426","Effects of Semaglutide on Brain Dopamine Responses to Food Cues in Adults With Obesity and Food Addiction Tendencies","A Prospective Clinical Study to Investigate Dopamine Level Changes in the Brain at Food Cognition by GLP-1 Receptor Agonists","Inclusion Criteria:\n\n* Participants aged between 19 and 50 years.\n* Eligible for treatment with semaglutide, defined as either:\n* Initial body mass index (BMI) of 30 kg\u002Fm2 or higher; or\n* Initial BMI of 27 kg\u002Fm2 to less than 30 kg\u002Fm2 with at least one weight-related comorbidity, such as dysglycemia, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease.\n* Mild or greater food addiction tendency, defined as a Yale Food Addiction Scale (YFAS) score of 3 or higher.\n* Able to understand the study tasks and provide appropriate responses.\n\nExclusion Criteria:\n\n* Use of medications that may affect body weight or dopaminergic medications within the past 2 months.\n* Known hypersensitivity to semaglutide.\n* Pregnant, breastfeeding, or planning to become pregnant.\n* Severe renal impairment, hepatic impairment, heart failure, acute pancreatitis, or thyroid disease.\n* Any medical condition, disease, or medical history that, in the investigator's judgment, would make it difficult for the participant to complete the study or would interfere with interpretation of the study results.\n* Allergy to ingredients in chocolate milk, including milk or soy, or to ingredients that may be present through cross-contamination, including egg, buckwheat, peanut, wheat, peach, tomato, walnut, pork, or beef.\n* Participants with both no self-reported preference for chocolate milk and a chocolate milk preference score of less than 5 on a 10-point visual analog scale (VAS).","50 Years",{"count":83,"type":21},[24],"The goal of this clinical trial is to investigate how semaglutide affects the way the brain responds to food in adults with obesity and food addiction tendencies.\n\nThe main goals of this study are:\n\n* To see if semaglutide changes dopamine-related activity in the brain during the look, smell, and drink period.\n* To see if semaglutide changes dopamine-related brain signals during the post-ingestive period.\n* To see if semaglutide changes psychological survey results and cognitive task results.\n\nAdults with obesity and food addiction tendencies will join this study. Each participant will receive semaglutide treatment for 8 weeks. Each participant will have two brain scans using \\[11C\\]raclopride PET.\n\nDuring each PET scan, participants will:\n\n* View food images.\n* Receive chocolate milk through a tube while lying in the scanner.\n* Use a tablet during the scan to rate their hunger, desire for the chocolate milk drink, and liking of the drink.",[428,429,430],"Food Addiction Tendency","Obesity","Overweight","2026-07-23",{"date":380,"type":36},{"date":434,"type":36},"2026-07-15",{"date":436,"type":21},"2028-06-30",{"name":42,"class":43},{"id":439,"slug":440,"hasResults":12,"nctId":441,"briefTitle":442,"officialTitle":442,"acronym":443,"eligibilityCriteria":444,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":445,"targetDuration":4,"studyType":22,"phases":447,"briefSummary":448,"conditions":449,"keywords":450,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":455,"startDateStruct":456,"completionDateStruct":457,"leadSponsor":458,"locationsCount":459},"100630366","functional-and-structural-assesment-of-the-heart-by-artificial-intelligence-enabled-electrocardiogram-for-the-management-of-atrial-fibrillation-100630366","NCT07486739","Functional And STructural Assesment of the Heart by Artificial Intelligence-enabled Electrocardiogram for the Management of Atrial Fibrillation","FAST-AF","Inclusion Criteria:\n\n1. AF documented by electrocardiography within the past 12 months\n\n   * AF documented on a 12-lead electrocardiogram or recorded for ≥30 seconds on a single-lead or multi-lead electrocardiogram.\n2. Patients for whom an initial or repeat transthoracic echocardiographic evaluation is clinically indicated.\n3. A CHA₂DS₂-VA score of ≥2.\n4. Aged ≥19 years at the time of enrollment and able to provide written informed consent voluntarily.\n\nExclusion Criteria:\n\n1. Transthoracic echocardiography performed within the past 6 months.\n2. Ventricular rate ≥110 beats per minute during atrial fibrillation.\n3. Atrial fibrillation due to a reversible cause.\n4. New York Heart Association (NYHA) functional class IV or European Heart Rhythm Association (EHRA) class IV symptoms.\n5. Known history of structural heart disease or clinical findings suggestive of structural heart disease based on medical history and physical examination. (e.g., presence of a cardiac murmur of Levine scale grade 3 or higher on auscultation, or murmurs suggestive of moderate to severe mitral stenosis, such as an opening snap or diastolic rumbling murmur).\n6. Baseline electrocardiographic conduction abnormalities or significant electrocardiographic findings suggestive of clinically meaningful structural heart disease (e.g., Mobitz type II second-degree atrioventricular block, third-degree atrioventricular block, or QTc ≥480 ms).\n7. History of prior cardiac surgery.\n8. History of acute coronary syndrome or coronary revascularization within the past 90 days.\n9. History of intracardiac thrombosis or systemic thromboembolism within the past 90 days.\n10. History of transient ischemic attack, ischemic stroke, or intracranial hemorrhage within the past 90 days.\n11. History of ventricular tachycardia or ventricular fibrillation.\n12. Severe liver disease associated with coagulopathy (e.g., AST or ALT \\>3× the upper limit of normal, or total bilirubin \\>2× the upper limit of normal).\n13. Severe chronic kidney disease (stage V), requiring or imminently requiring dialysis.\n14. Contraindication to anticoagulation therapy.\n15. Pregnancy, breastfeeding, or planning pregnancy during the study period.\n16. Life expectancy of less than 1 year.\n17. Current participation in another randomized clinical trial.",{"count":446,"type":21},1724,[24],"The objective of this study is to evaluate whether an AI-ECG based screening strategy for detecting cardiac functional and structural abnormalities preserves clinical effectiveness and safety, compared with a conventional strategy of routine echocardiography in patients with AF, thereby demonstrating the non-inferiority of AI-ECG guided care.",[27],[29,451,452,453],"artificial intelligence","structural heart disease","electrocardiogram","2026-07-22",{"date":431,"type":36},{"date":352,"type":21},{"date":70,"type":21},{"name":42,"class":43},28,{"id":461,"slug":462,"hasResults":12,"nctId":463,"briefTitle":464,"officialTitle":465,"acronym":4,"eligibilityCriteria":466,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":467,"targetDuration":4,"studyType":22,"phases":469,"briefSummary":470,"conditions":471,"keywords":4,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":474,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":479,"locationsCount":4},"100647068","first-attempt-success-in-tracheal-intubation-through-supraglottic-airway-devices-without-fiberoptic-guidance-100647068","NCT07704723","First Attempt Success in Tracheal Intubation Through Supraglottic Airway Devices Without Fiberoptic Guidance","First Attempt Success in Tracheal Intubation Through Supraglottic Airway Devices Without Fiberoptic Guidance: Conventional vs. Video-assisted Supraglottic Airway Devices, a Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged 19 years or older.\n* Scheduled to undergo elective surgery under general anesthesia requiring tracheal intubation.\n\nExclusion Criteria:\n\n* Refusal or inability to provide informed consent.\n* Emergency surgery.\n* History of gastroesophageal reflux disease.\n* Previous surgery or radiotherapy involving the upper airway.\n* Severely loose teeth.\n* Any condition considered by the investigator to make study participation inappropriate.",{"count":468,"type":21},204,[24],"This randomized controlled trial aims to compare the first-attempt success rate of tracheal intubation through supraglottic airway devices using a conventional intubating supraglottic airway device versus a video-assisted supraglottic airway device without fiberoptic guidance in adult patients undergoing elective surgery under general anesthesia. A total of 204 participants will be randomly assigned to one of the two groups. The primary outcome is the first-attempt success rate of tracheal intubation through the supraglottic airway device. Secondary outcomes include intubation time, number of intubation attempts, overall intubation success, hemodynamic changes, airway-related complications, postoperative sore throat and hoarseness, and adverse events. The results of this study may help identify a safe and effective airway management strategy when fiberoptic bronchoscopy is unavailable.",[472],"Airway Management","2026-07-09",{"date":434,"type":36},{"date":476,"type":21},"2026-08-01",{"date":478,"type":21},"2029-08-01",{"name":42,"class":43},{"id":481,"slug":482,"hasResults":12,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":4,"eligibilityCriteria":486,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":125,"enrollmentInfo":487,"targetDuration":4,"studyType":22,"phases":489,"briefSummary":490,"conditions":491,"keywords":496,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":511,"startDateStruct":513,"completionDateStruct":514,"leadSponsor":516,"locationsCount":44},"100645791","phase-4-intravenous-dexamethasone-with-single-shot-versus-continuous-brachial-plexus-block-for-rebound-pain-after-shoulder-surgery-100645791","NCT07699744","Intravenous Dexamethasone With Single-Shot Versus Continuous Brachial Plexus Block for Rebound Pain After Shoulder Surgery","Pain Management Protocol Optimization for Rebound Pain Prevention and Enhanced Recovery After Shoulder Surgery: A Randomized Noninferiority Trial of Intravenous Dexamethasone Combined With Single-Shot Versus Continuous Brachial Plexus Block","Inclusion Criteria:\n\n* Adult patients aged 19 to 79 years scheduled for elective shoulder surgery under brachial plexus block and monitored anesthesia care (MAC)\n\nExclusion Criteria:\n\n* Pre-existing neurological deficit of the brachial plexus\n* Emergency surgery\n* American Society of Anesthesiologists (ASA) physical status classification IV or higher\n* Contraindication or history of hypersensitivity to local anesthetics or dexamethasone\n* Severe pulmonary disease (e.g., chronic obstructive pulmonary disease)\n* Body mass index (BMI) ≥ 35 kg\u002Fm²\n* Long-term use of steroids\n* Long-term use of analgesics\n* Inability to cooperate or communicate\n* Pregnancy",{"count":488,"type":21},92,[346],"Shoulder surgery often causes severe pain after the operation. To control this pain, doctors commonly perform a nerve block (interscalene brachial plexus block), which numbs the shoulder area. However, when the effect of a single-injection nerve block wears off, many patients experience sudden, intense pain known as \"rebound pain\".\n\nOne way to prevent rebound pain is to place a thin catheter near the nerves so that local anesthetic can be given continuously for a longer period (continuous nerve block). However, this method is technically demanding and can cause problems such as catheter dislodgement, infection, and inconvenience for patients. Another simpler option is to give a single-injection nerve block together with an intravenous (IV) injection of dexamethasone, a steroid medication known to prolong the effect of nerve blocks and reduce rebound pain.\n\nThe purpose of this study is to determine whether a single-injection nerve block combined with IV dexamethasone (5 mg) is not inferior to a continuous nerve block in preventing rebound pain after shoulder surgery. A total of 92 adult patients scheduled for elective shoulder surgery will be randomly assigned to one of the two groups. The main outcome is the rebound pain score, defined as the difference between the last pain score recorded in the recovery room (while the nerve block is still working) and the highest pain score reported within the first 24 hours after the nerve block. The investigators expect that the simpler single-injection method with IV dexamethasone will provide comparable pain control while avoiding the complications and inconvenience of catheter-based continuous nerve blocks.",[492,493,494,495],"Pain, Postoperative","Rebound Pain","Shoulder Injuries","Rotator Cuff Injuries",[497,498,499,500,501,502,503,504,505,506,507,508,509,510],"Rebound pain","Interscalene brachial plexus block","Single-shot nerve block","Continuous peripheral nerve block","Perineural catheter","Dexamethasone","Intravenous dexamethasone","Shoulder surgery","Rotator cuff repair","Regional anesthesia","Postoperative analgesia","Multimodal analgesia","Non-inferiority trial","Enhanced recovery after surgery",{"date":512,"type":36},"2026-07-13",{"date":434,"type":21},{"date":515,"type":21},"2027-07-15",{"name":42,"class":43},{"id":518,"slug":519,"hasResults":12,"nctId":520,"briefTitle":521,"officialTitle":522,"acronym":4,"eligibilityCriteria":523,"healthyVolunteers":12,"sex":17,"minAge":524,"maxAge":4,"enrollmentInfo":525,"targetDuration":4,"studyType":22,"phases":527,"briefSummary":528,"conditions":529,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":115},"100533410","individualized-versus-conventional-perioperative-blood-pressure-management-100533410","NCT06225453","Individualized Versus Conventional Perioperative Blood Pressure Management","Effect of Individualized Versus Conventional Blood Pressure Management on Major Adverse Cardiac, Cerebrovascular, and Renal Events After Major Non-cardiac Surgery: Multicenter, Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients aged ≥65 or,\n* those aged ≥45 with a history of coronary artery disease, peripheral vascular disease, transient ischemic attack\u002Fstroke, or congestive heart failure,\n* undergoing non-cardiac surgery under general anesthesia with an anticipated duration of ≥2 hours.\n\nExclusion Criteria:\n\n* Emergency surgery\n* Organ transplantation surgery\n* Brain\u002Fcarotid artery surgery\n* American Society of Anesthesiologists physical status 5 or 6\n* Pregnancy\n* Uncontrolled preoperative hypertension (systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg)\n* Estimated glomerular filtration rate \\\u003C30 ml\u002Fmin\u002F1.73m2\n* Renal replacement therapy\n* Acute decompensated heart failure\n* Sepsis\n* Shock\n* Use of inotropes\u002Fvasopressor infusion (dopamine, norepinephrine, vasopressin, etc.)","45 Years",{"count":526,"type":21},1896,[24],"Study objective: To compare the effect of different perioperative blood pressure management strategies on major postoperative adverse outcomes \u002F Study design: a multicenter, randomized controlled trial \u002F Participants: 1896 patients undergoing major non-cardiac surgery \u002F Methods: Patients are randomized into two groups, the individualized strategy (maintaining perioperative mean arterial pressure and systolic blood pressure more than -20% of their baseline values) or the conventional strategy (maintaining perioperative mean arterial pressure ≥65 mmHg and systolic blood pressure ≥90 mmHg in all patients). Then, the frequency of major postoperative adverse outcomes occurring within 7 postoperative days or before discharge (whichever occurs first). \u002F Primary outcome: a composite of all-cause death, stroke, myocardial infarction, new or worsening congestive heart failure, unplanned coronary revascularization, and acute kidney injury, occuring within 7 postoperative days or before discharge (whichever occurs first).",[530],"Major Non-cardiac Surgery","2026-07-05",{"date":533,"type":36},"2026-07-07",{"date":535,"type":36},"2024-01-29",{"date":537,"type":21},"2026-12-31",{"name":42,"class":43},{"id":540,"slug":541,"hasResults":12,"nctId":542,"briefTitle":543,"officialTitle":544,"acronym":4,"eligibilityCriteria":545,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":546,"targetDuration":4,"studyType":22,"phases":548,"briefSummary":549,"conditions":550,"keywords":4,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":553,"startDateStruct":555,"completionDateStruct":557,"leadSponsor":559,"locationsCount":4},"100647056","comparison-of-first-attempt-success-based-on-endotracheal-tube-type-during-videolaryngoscope-guided-intubation-without-stylet-100647056","NCT07682480","Comparison of First Attempt Success Based on Endotracheal Tube Type During Videolaryngoscope-guided Intubation Without Stylet","Comparison of First Attempt Success Based on Endotracheal Tube Type During Videolaryngoscope-guided Intubation Without Stylet: Prospective Non-inferiority Comparison","Inclusion Criteria:\n\n* Adults aged 19 years or older\n* Scheduled to undergo surgery under general anesthesia\n\nExclusion Criteria:\n\n* Refusal to participate in the study\n* History of gastroesophageal reflux disease\n* Inadequate preoperative fasting\n* Congenital or acquired upper airway abnormalities (e.g., tumors, polyps, trauma, abscesses, inflammation, foreign bodies)\n* History of upper airway surgery\n* High risk of aspiration or bleeding tendency\n* Presence of severely loose teeth",{"count":547,"type":21},246,[24],"Patients are randomly assigned to either the oral RAE tube group (Group O) or the reinforced tube group (Group R). In both groups, tracheal intubation is performed using a videolaryngoscope without a stylet, and the first-attempt success rate is compared. Upon emergence from anesthesia and removal of the endotracheal tube, the degree of subglottic injury is assessed and compared between the groups. In addition, postoperative sore throat and hoarseness are evaluated and compared at 1 hour and 24 hours after surgery.",[551],"Intubation Complication","2026-06-28",{"date":554,"type":36},"2026-07-06",{"date":556,"type":21},"2026-12-01",{"date":558,"type":21},"2028-04-17",{"name":42,"class":43},{"id":561,"slug":562,"hasResults":12,"nctId":563,"briefTitle":564,"officialTitle":565,"acronym":566,"eligibilityCriteria":567,"healthyVolunteers":12,"sex":17,"minAge":568,"maxAge":4,"enrollmentInfo":569,"targetDuration":4,"studyType":22,"phases":571,"briefSummary":572,"conditions":573,"keywords":575,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":588,"lastUpdatePostDateStruct":589,"startDateStruct":591,"completionDateStruct":593,"leadSponsor":595,"locationsCount":596},"100644919","phase-3-a-6-month-mdr-end-plus-regimen-for-rifampicin-resistant-tuberculosis-100644919","NCT07675954","A 6-Month MDR-END Plus Regimen for Rifampicin-Resistant Tuberculosis","A Phase 3, Open-Label, Randomised Controlled Trial to Evaluate a 6-Month \"MDR-END Plus\" Regimen (Bedaquiline, Delamanid, Delpazolid, Levofloxacin and Pyrazinamide) Versus the South African Standard of Care Treatment for Rifampicin-Resistant Tuberculosis","MDR-ENDPlus","Inclusion Criteria:\n\n1. Willing and able to voluntarily provide written informed consent to participate in the study prior to initiation of any study-related procedures. For participants under the age of 18 years, signed consent may be obtained from the child's biological parent, legal guardian, or primary caregiver in the presence of the child. Minor participants must also be willing to provide written assent for study participation.\n2. To the best of their knowledge and abilities at screening, participants must be willing and able to adhere to the complete follow-up schedule and all study procedures.\n3. Male or female participants aged 15 years or older.\n4. Participant requires treatment for pulmonary rifampicin-resistant tuberculosis based on one or more of the following:\n\n   * Documented molecular drug susceptibility testing, such as TB nucleic acid amplification test, line probe assay, targeted next-generation sequencing, or culture-based phenotypic drug susceptibility testing on a sample obtained from the participant within 8 weeks prior to screening, even if rifampicin resistance is not re-confirmed on a sample obtained at screening; or\n   * Documented or self-reported clinical symptoms or signs of pulmonary tuberculosis disease, with or without radiological changes consistent with pulmonary tuberculosis, and evidence of close contact with someone with confirmed rifampicin-resistant tuberculosis which, in the opinion of the site investigator, indicates significant exposure and a clinical decision has been made to treat the participant for rifampicin-resistant tuberculosis in routine care; or\n   * Documented peripheral tuberculosis lymphadenitis or tuberculosis pleurisy with confirmed rifampicin-resistant Mycobacterium tuberculosis on lymph node biopsy or pleural fluid aspiration, along with documented symptoms or signs suggestive of pulmonary tuberculosis without culture confirmation.\n5. Not yet started rifampicin-resistant tuberculosis treatment, or initiated rifampicin-resistant tuberculosis treatment in routine care within 10 days prior to enrolment.\n6. Body weight of at least 30 kg.\n7. Documented HIV status and\u002For willing to undergo HIV testing.\n8. Participants living with HIV must be on antiretroviral therapy, or due to start antiretroviral therapy within 2 months of enrolment, regardless of CD4 count, provided they are clinically stable in the opinion of the site investigator.\n9. Pregnant women in any trimester and breastfeeding women are eligible for inclusion.\n\nExclusion Criteria:\n\n1. Two or more of the following four drug groups cannot be used: bedaquiline or clofazimine; delamanid or pretomanid; linezolid or delpazolid; levofloxacin or moxifloxacin, due to any of the following:\n\n   * Documented Mycobacterium tuberculosis resistance in the current or prior treatment episode;\n   * Prior exposure of 1 month or longer, unless protocol-defined exceptions are met;\n   * Absolute contraindications to the relevant study drugs;\n   * Use of prohibited concomitant medications within 14 days prior to enrolment.\n2. Ongoing treatment for rifampicin-resistant tuberculosis for more than 10 days in the current tuberculosis episode.\n3. Isolated extrapulmonary tuberculosis without pulmonary involvement.\n4. Extrapulmonary tuberculosis, with or without concurrent pulmonary tuberculosis, involving the central nervous system, osteoarticular sites, pericardium, or disseminated\u002Fmiliary disease.\n5. Any of the following laboratory or ECG abnormalities:\n\n   A. Alanine transaminase or aspartate transaminase \\>120 U\u002FL; B. Total bilirubin \\>2.4 mg\u002FdL; C. Estimated glomerular filtration rate by the CKD-EPI equation \\\u003C30 mL\u002Fmin\u002F1.73 m²; D. Serum potassium \\\u003C3.2 mmol\u002FL; E. QTcF \\>480 msec.\n6. Atrioventricular block, second or third degree; current or previous history of clinically significant ventricular arrhythmias or long QT syndrome; or family history of long QT syndrome or sudden cardiac death.\n7. Any condition or circumstance which, in the opinion of the investigator, based on information available at the time of screening, raises concerns regarding the participant's safety or ability to participate in the trial or the integrity of the study data.","15 Years",{"count":570,"type":21},294,[275],"This is a phase 3, open-label, randomized clinical trial in adults and adolescents aged 15 years or older who need treatment for rifampicin-resistant tuberculosis in South Africa.\n\nThe goal of this clinical trial is to learn whether a 6-month MDR-END Plus regimen works as well as current standard of care (SoC) treatment for rifampicin-resistant tuberculosis. The trial will also learn whether the MDR-END Plus regimen is safer and easier to tolerate than SoC regimens.\n\nThe main questions this trial aims to answer are:\n\n* Does the MDR-END Plus regimen lead to a favorable treatment outcome 12 months after treatment is stopped, compared with SoC regimens?\n* Do participants receiving the MDR-END Plus regimen have fewer important safety or tolerability problems during treatment and up to 90 days after treatment is stopped, compared with SoC regimens?\n\nResearchers will compare the MDR-END Plus regimen with South African standard of care (SoC) treatment for rifampicin-resistant tuberculosis.\n\nParticipants will:\n\n* Be randomly assigned to receive either the MDR-END Plus regimen or SoC treatment.\n* Take tuberculosis medicines for about 6 months, although treatment may be extended in some cases.\n* Attend study visits during treatment and after treatment is stopped.\n* Have clinical assessments, blood tests, heart tracing tests, vision and nerve assessments, and tuberculosis tests.\n* Be followed for 12 months after treatment is stopped.",[574],"Rifampicin-Resistant Tuberculosis",[576,577,578,579,580,581,582,583,584,585,586,587],"Rifampicin-resistant tuberculosis","Multidrug-resistant tuberculosis","MDR-TB","RR-TB","Bedaquiline","Delamanid","Delpazolid","Levofloxacin","Pyrazinamide","MDR-END Plus","Short treatment regimen","South Africa","2026-06-23",{"date":590,"type":36},"2026-06-30",{"date":592,"type":21},"2026-10-01",{"date":594,"type":21},"2032-06",{"name":42,"class":43},2,{"id":598,"slug":599,"hasResults":12,"nctId":600,"briefTitle":601,"officialTitle":602,"acronym":4,"eligibilityCriteria":603,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":125,"enrollmentInfo":604,"targetDuration":4,"studyType":22,"phases":606,"briefSummary":607,"conditions":608,"keywords":611,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":588,"lastUpdatePostDateStruct":614,"startDateStruct":615,"completionDateStruct":616,"leadSponsor":618,"locationsCount":44},"100644876","phase-4-efficacy-and-safety-of-eleveld-pkpd-model-based-dosing-during-general-anesthesia-100644876","NCT07675850","Efficacy and Safety of Eleveld PK\u002FPD Model-based Dosing During General Anesthesia","Comparison of Efficacy and Safety Between Eleveld PK\u002FPD Model-based Dosing and Standard Dosing During General Anesthesia","Inclusion Criteria:\n\n* Patients aged 19 to 79 years undergoing elective non-cardiac surgery expected to last 60 minutes or longer under general anesthesia with endotracheal intubation\n\nExclusion Criteria:\n\n* Emergency surgery\n* Surgery requiring evoked potential (EP) monitoring\n* Chronic benzodiazepine users\n* Body Mass Index (BMI) ≥ 35 kg\u002F㎡\n* Chronic kidney disease\n* Hepatic dysfunction or chronic liver disease\n* Contraindication or history of hypersensitivity to remimazolam\n* American Society of Anesthesiologists (ASA) physical status ≥ IV\n* Pregnant women\n* Contraindication or history of hypersensitivity to flumazenil",{"count":605,"type":21},68,[346],"The goal of this randomized, controlled clinical trial is to evaluate the efficacy, safety, and recovery profile of an individualized, Eleveld pharmacokinetic\u002Fpharmacodynamic model-guided dosing strategy for remimazolam in adult patients undergoing elective non-cardiac surgery under general anesthesia.\n\nThe main questions it aims to answer are:\n\nDoes Eleveld model-guided customized dosing significantly reduce the eye-opening time at the end of surgery compared to standard weight-based dosing?\n\nCan the Eleveld model-guided approach prevent relative drug accumulation and delayed emergence while maintaining an adequate depth of anesthesia and comparable hemodynamic stability?\n\nResearchers will compare the Experimental Group (Eleveld model-guided dosing) to the Control Group (Standard weight-based label dosing) to see if preemptive dose optimization based on individual patient covariates effectively reduces the total drug consumption, frequency of rescue flumazenil administration, and emergence time.\n\nParticipants will:\n\n* Be randomly assigned to receive remimazolam for the induction and maintenance of general anesthesia according to either the Eleveld model-guided customized regimen or the standard weight-based regimen.\n* Have their depth of anesthesia continuously monitored using a Bispectral Index (BIS) sensor.\n* Be assessed for the primary outcome (time to eye-opening upon verbal command after discontinuation of anesthetics) and secondary outcomes, including total drug consumption, hemodynamic stability, and postoperative complications (e.g., re-sedation, delirium, PONV).",[609,610],"Remimazolam","Pharmacokinetics and Pharmacodynamics",[609,612,613],"general anesthesia","pharmacokinetics and pharmacodynamics",{"date":590,"type":36},{"date":354,"type":21},{"date":617,"type":21},"2027-05-31",{"name":42,"class":43},{"id":620,"slug":621,"hasResults":12,"nctId":622,"briefTitle":623,"officialTitle":624,"acronym":4,"eligibilityCriteria":625,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":626,"targetDuration":4,"studyType":154,"phases":4,"briefSummary":627,"conditions":628,"keywords":629,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":588,"lastUpdatePostDateStruct":631,"startDateStruct":633,"completionDateStruct":635,"leadSponsor":637,"locationsCount":44},"100622557","perioperative-continuous-glucose-monitoring-accuracy-in-cardiac-surgery-100622557","NCT07385170","Perioperative Continuous Glucose Monitoring Accuracy in Cardiac Surgery","Evaluation of Perioperative Continuous Glucose Monitoring Accuracy in Patients Undergoing Cardiac Surgery","Inclusion Criteria:\n\n* Patients aged 19 years or older scheduled for cardiac surgery\n\nExclusion Criteria:\n\n* Skin disease at the sensor application site (proximal arm)",{"count":55,"type":21},"The goal of this clinical trial is to evaluate accuracy of continuous glucose monitoring device called 'Dexcom G7' in patients undergoing cardiac surgery.",[349],[630],"continuous glucose monitoring",{"date":632,"type":36},"2026-06-26",{"date":634,"type":36},"2026-05-27",{"date":636,"type":21},"2028-05-31",{"name":42,"class":43},""]